Medtronic Fiscal Year-End

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of the Company. Medtronic fiscal year-end is filed June 27,17for the Period Ending April28,17. Medtronic is among the world's largest medical technology, services, and solutions companies for restoring health, reducing pain and extending life for millions of people around the world. Medtronic employs more than 91,000 full-time employees worldwide, serving physicians, hospitals, and patients in approximately 160 countries. Medtronic’s primary products include those for cardiac rhythm disorders, cardiovascular disease, advanced and general surgical care, respiratory and monitoring

This is representing an increase of 14 percent and 17 percent, correspondingly. The currency translation had an uncomplimentary of $34 million on net sales for fiscal year 2017 , as compared to fiscal year 2016 when using the average exchange rates in effect during fiscal year 2016 . In addition, the fiscal year 2017 acquisitions of HeartWare and Smith & Nephew's gynecology business contributed $200 million to our total net sales growth. Medtronic performance has three growth strategies which are therapy innovation, globalization, and economic value. Medtronic created competitive advantages by exploiting the long-term trends in healthcare. Medtronic uses the continued desire to improve clinical outcomes; the growing demand for expanded access to care; and the optimization of cost and efficiency within healthcare systems. In Medtronic’s therapy innovation growth strategy and economic value, we continue to see strong adoption of our products across all our operating

Price adjustment rebates charged against gross sales were $3.0 billion and $2.9 billion in fiscal years 2017 and 2016 , respectively, and $679 million for the fourth quarter of fiscal year 2015.Medtronic tests definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. Definite-lived intangible assets, net of accumulated amortization, were $22.8 billion and $26.2 billion at April 28, 2017 and April 29, 2016 , respectively. Indefinite-lived intangible assets were $594 million and $721 million at April 28, 2017 and April 29, 2016.Since 2015 we operate under four reportable segments and four operating segments, the Cardiac and Vascular Group the Minimally Invasive Therapies Group, the Restorative Therapies Group, and the Diabetes Group. Cardiac Rhythm & Heart Failure net sales for fiscal year 2017 were $5.6 billion , an increase of 3 percent compared to fiscal year 2016. Cardiac Rhythm & Heart Failure net sales growth for fiscal year 2017 was driven by strong due to growth in AF Solutions and Diagnostics. The strong growth in AF Solutions was driven by the continued global acceptance of our Arctic Front Advance Cardiac CryoAblation Catheter (Arctic Front) system. Coronary & Structural Heart net sales for fiscal year 2017 were $3.1 billion , an increase of 1 percent compared to fiscal